Table 3.
Comparison of safety parameters for toxicity evaluation pre and 8 weeks post Lu177-PSMA therapy by Wilcoxon signed-rank test
| Parameters | Pre therapy | Post therapy | P value | |||
|---|---|---|---|---|---|---|
| Absolute value (mean ± SD) | CTCEA grade (0–5) (Mean ± SD) |
Absolute value (mean ± SD) | CTCEA grade (0–5) (Mean ± SD) |
For absolute value | For CTCEA grade | |
| Hb (g/dl) | 10.41 ± 1.55 | 1.36 ± 0.73 | 10.05 ± 1.89 | 1.73 ± 0.88 | 0.073 | <0.05 |
| TLC (per mm3) | 8123.50 ± 2425.53 | 0 ± 0 | 6761.14 ± 2474.70 | 0.45 ± 0.21 | 0.001 | 1.000 |
| Platelets (lac/mm3) | 3.36 ± 1.27 | 0 ± 0 | 2.50 ± 0.79 | 0 ± 0 | 0.001 | 1.000 |
| Creatinine (mg/dl) | 143.32 ± 142.84 | 0.09 ± 0.29 | 133.99 ± 159.21 | 0.13 ± 0.47 | 0.568 | 0.317 |
| Total bilirubin (mg/dl) | 0.89 ± 0.15 | 0 ± 0 | 0.85 ± 0.14 | 0 ± 0 | 0.496 | 1.000 |
| DTPA GFR (ml/min) | 71.82 ± 13.13 | 0.14 ± 0.35 | 71.41 ± 13.74 | 0.18 ± 0.39 | 0.307 | 0.307 |
Lu177-PSMA lutetium 177 prostate-specific membrane antigen, Hb haemoglobin, TLC total leukocyte count, DTPA diethylenetriaminepentaacetic acid, GFR glomerular filtration rate, CTCAT Common Terminology Criteria for Adverse Events version 4.03